Laekna, Inc. (2105.HK) Announces Interim Results 2023 ...Middle East

PR Newswire - News
For the Phase II pivotal trial of Afuresertib (LAE002) + Paclitaxel for platinum-resistant recurrent ovarian cancer (PROFECTOR-II), the patients were fully enrolled and the topline data is expected in the late fourth quarter of 2023 For the Phase Ib/III trial of Afuresertib + Fulvestrant...

Hence then, the article about laekna inc 2105 hk announces interim results 2023 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Laekna, Inc. (2105.HK) Announces Interim Results 2023 )

Apple Storegoogle play

Last updated :

Also on site :